https://doi.org/10.4081/mm.2021.9695
Humoral immunity after Pfizer/BioNTech BNT162b2 vaccine in healthcare workers of ASL Roma 2 (Italy)
Submitted: 19 February 2021
Accepted: 29 April 2021
Published: 28 October 2021
Accepted: 29 April 2021
Abstract Views: 481
PDF: 191
HTML: 3
HTML: 3
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
The Unit (COU) of Microbiology and Virology of Sandro Pertini Hospital began monitoring the immune response on a cohort of healthcare operators who received the Pfizer/BioNTech BNT162b2 vaccine. Three different tests for the detection of antibodies against SARS-CoV-2 were used showing 100% of seroconversion after 28 days from the first dose.
How to Cite
Giberna, E., Guastafierro, T., Ciaffi, N. ., Nebuloso, E., Piccoli, S., Serao, M., Gioffrè, G., Campitelli, S., Colace, M. G., Cava, M. C., & De Cristofaro, M. . (2021). Humoral immunity after Pfizer/BioNTech BNT162b2 vaccine in healthcare workers of ASL Roma 2 (Italy). Microbiologia Medica, 36(2). https://doi.org/10.4081/mm.2021.9695
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.